Intellia Therapeutics, Inc (NTLA)
Nasdaq · Common stock · In Vitro & In Vivo Diagnostic Substances
As of Oct 21, 2:34 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow NTLA in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on NTLA and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
NTLA at a glance
Key statistics
$1.66B
Market capitalization
- Previous close
- $11.84
- Open
- $11.87
- Day range
- $11.55 – $11.91
- Volume
- 1.48M
- Average volume (30 sessions)
- 5.44M
- Shares outstanding
- 140.13M
- Earnings per share
- $(2.85)
- Price / book
- 2.3
- Price / sales
- 27.9
- Beta (1 year, vs SPY)
- 2.25
Where the price sits in its year
52-week range
18% of the range
- Below the 52-week high
- -58.9%
- Above the 52-week low
- +46.0%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $12.04-1.6%
- 50-day average
- $12.25-3.3%
- 200-day average
- $13.02-9.1%
Between the conventional 30 and 70 bands.
-0.6%
1 week
-3.1%
1 month
+6.4%
3 months
+31.7%
Year to date
-52.2%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with NTLA
NTLA on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on NTLA.
See the plans →
Every planScreen names like NTLA
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on NTLA
Put NTLA on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on NTLA
See whether there is an open premium alert on NTLA, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
NTLA headlines
- Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
GlobeNewswire Inc. · Sep 4, 2026
- Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire Inc. · Sep 4, 2026
- Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
GlobeNewswire Inc. · Jun 13, 2026
- Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewswire Inc. · Apr 29, 2026
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc. · Apr 3, 2026
- Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
Benzinga · Sep 25, 2025
- Intellia Therapeutics Shares Are Ripping Higher: Here's Why
Benzinga · Sep 18, 2025
- Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
GlobeNewswire Inc. · Jun 15, 2025
SEC Form 4, most recent first
Insider filings
Dube Michael P
−1.9K
VP, Chief Accounting Officer · Open-market sale
$23.17K · Oct 2, 2026
LEONARD JOHN M
−19.9K
President and CEO, Director · Open-market sale
$250.61K · Aug 20, 2026
LEONARD JOHN M
−2.8K
President and CEO, Director · Open-market sale
$36.20K · Aug 21, 2026
Dulac Edward J III
−8.1K
EVP, Chief Financial Officer · Open-market sale
$91.25K · Jul 22, 2026
Dulac Edward J III
−4.7K
EVP, Chief Financial Officer · Open-market sale
$84.19K · Jul 2, 2026
Dube Michael P
−2.6K
VP, Chief Accounting Officer · Open-market sale
$44.32K · Jul 1, 2026
Bhanji Muna
+9.2K
Director · Grant or award
· Jun 9, 2026
Cohen Fred E
+9.2K
Director · Grant or award
· Jun 9, 2026
About Intellia Therapeutics, Inc
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Headquarters
- Cambridge, MA
- Employees
- 377
- Listed since
- May 6, 2016
- Website
- intelliatx.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.